Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jul 10;38(20):2281-2289.
doi: 10.1200/JCO.19.02576. Epub 2020 May 22.

Locoregional Management After Neoadjuvant Chemotherapy

Monica Morrow  1 , Atif J Khan  2
Affiliations
Review

Locoregional Management After Neoadjuvant Chemotherapy

Monica Morrow et al. J Clin Oncol. .
No abstract available

PubMed Disclaimer

Figures

FIG 1.
FIG 1.
Diagram of ongoing phase III trials of locoregional therapy after neoadjuvant chemotherapy (NAC). Trial schemas are depicted for ongoing studies examining extent of radiation based on response to NAC. ALND, axillary lymph node dissection; Bx, biopsy; ER, estrogen receptor; FNA, fine-needle aspiration; HER2, human epidermal growth factor receptor 2; NSABP, National Surgical Adjuvant Breast and Bowel Project; pCR, pathologic complete response; PMRT, postmastectomy radiation therapy; PR, progesterone receptor; RT, radiation therapy; RTOG, Radiation Therapy Oncology Group; SN, sentinel node; WBRT, whole-breast radiation therapy.
FIG 2.
FIG 2.
Coronal projection of axillary clinical target volume excluding axillary lymph node dissection (ALND) changes. Clips from ALND are visible in the low axilla. The axillary clinical target volume (CTV) contour (in red) begins above the visible dissection changes. The supraclavicular CTV contour appears medial and superior to the axillary CTV (orange contour).
See this image and copyright information in PMC

References

    1. Bonadonna G, Veronesi U, Brambilla C, et al. Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J Natl Cancer Inst. 1990;82:1539–1545. - PubMed
    1. Fisher B, Brown A, Mamounas E, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol. 1997;15:2483–2493. - PubMed
    1. van der Hage JA, van de Velde CJ, Julien JP, et al. Preoperative chemotherapy in primary operable breast cancer: Results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol. 2001;19:4224–4237. - PubMed
    1. Golshan M, Cirrincione CT, Sikov WM, et al. Impact of neoadjuvant chemotherapy in stage II-III triple negative breast cancer on eligibility for breast-conserving surgery and breast conservation rates: Surgical results from CALGB 40603 (Alliance) Ann Surg. 2015;262:434–439. - PMC - PubMed
    1. Golshan M, Cirrincione CT, Sikov WM, et al. Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II-III HER2-positive breast cancer: Surgical results of CALGB 40601 (Alliance) Breast Cancer Res Treat. 2016;160:297–304. - PMC - PubMed

Publication types